Olga K Savushkina1, Elena B Tereshkina1, Tatiana A Prokhorova1, Irina S Boksha2, Denis S Burminskii1, Elena A Vorobyeva2, Margarita A Morozova1, Gulnur Sh Burbaeva1. 1. Federal State Budgetary Scientific Institution, Mental Health Research Centre, Laboratory of Neurochemistry, Moscow, Russia. 2. Federal State Budgetary Scientific Institution, Mental Health Research Centre, Laboratory of Neurochemistry, Moscow, Russia + Ministry of Health of the Russian Federation, Gamaleya Center of Epidemiology and Microbiology, Laboratory of Biologically Active Nanostructures, Moscow, Russia.
Abstract
BACKGROUND: Evaluation of possible relationship between platelet glutamate dehydrogenase (GDH) activity and mental state of schizophrenia patients after antipsychotic pharmacotherapy. METHODS: Patients (n = 50) with chronic paranoid schizophrenia (F20.0) initially in acute psychotic state were examined before and after a treatment course with antipsychotics. When assessing the patients' states using PANSS, the "responder" category was attributed to those patients who had not less than 30% reduction in the score for the corresponding PANSS "subscale". The control group (n = 48) was ageand gender-matched with the patient group. Platelet glutamate dehydrogenase (GDH) activity was measured in patients twice, before and after the treatment course, and once in controls. RESULTS: Significantly reduced GDH activity was found in patients compared with controls. The patient group was divided into two subgroups according to median GDH activity at baseline: above and below the median GDH, subgroup 1 and subgroup 2, respectively. GDH activity significantly increased from its level at baseline after antipsychotic treatment in subgroup 2. Distribution of non responders / responders to antipsychotic treatment (by PANSS scores) was significantly uneven among subgroups 1 and 2. In subgroup 1, GDH activity levels significantly correlated with PANSS scores after the treatment course. CONCLUSIONS: Baseline platelet GDH activity might serve as a predictor of antipsychotic therapy efficacy in schizophrenia patients. 2020 Olga K. Savushkina, Elena B. Tereshkina, Tatiana A. Prokhorova, Irina S. Boksha, Denis S. Burminskii, Elena A. Vorobyeva, Margarita A. Morozova, Gulnur Sh. Burbaeva, published by CEON/CEES.
BACKGROUND: Evaluation of possible relationship between platelet glutamate dehydrogenase (GDH) activity and mental state of schizophrenia patients after antipsychotic pharmacotherapy. METHODS: Patients (n = 50) with chronic paranoid schizophrenia (F20.0) initially in acute psychotic state were examined before and after a treatment course with antipsychotics. When assessing the patients' states using PANSS, the "responder" category was attributed to those patients who had not less than 30% reduction in the score for the corresponding PANSS "subscale". The control group (n = 48) was ageand gender-matched with the patient group. Platelet glutamate dehydrogenase (GDH) activity was measured in patients twice, before and after the treatment course, and once in controls. RESULTS: Significantly reduced GDH activity was found in patients compared with controls. The patient group was divided into two subgroups according to median GDH activity at baseline: above and below the median GDH, subgroup 1 and subgroup 2, respectively. GDH activity significantly increased from its level at baseline after antipsychotic treatment in subgroup 2. Distribution of non responders / responders to antipsychotic treatment (by PANSS scores) was significantly uneven among subgroups 1 and 2. In subgroup 1, GDH activity levels significantly correlated with PANSS scores after the treatment course. CONCLUSIONS: Baseline platelet GDH activity might serve as a predictor of antipsychotic therapy efficacy in schizophrenia patients. 2020 Olga K. Savushkina, Elena B. Tereshkina, Tatiana A. Prokhorova, Irina S. Boksha, Denis S. Burminskii, Elena A. Vorobyeva, Margarita A. Morozova, Gulnur Sh. Burbaeva, published by CEON/CEES.
Authors: Gulnur Sh Burbaeva; Marina S Turishcheva; Elena A Vorobyeva; Olga K Savushkina; Elena B Tereshkina; Irina S Boksha Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2002-04 Impact factor: 5.067
Authors: G Sh Burbaeva; I S Boksha; V G Kaleda; A N Barkhatova; M S Turishcheva; M A Omel'chenko; E B Tereshkina; O K Savushkina; L I Starodubtseva; T A Prokhorova; E A Vorob'eva Journal: Zh Nevrol Psikhiatr Im S S Korsakova Date: 2011
Authors: Hans-Gert Bernstein; Anne Tausch; Rebecca Wagner; Johann Steiner; Patrick Seeleke; Martin Walter; Henrik Dobrowolny; Bernhard Bogerts Journal: CNS Neurol Disord Drug Targets Date: 2013-11 Impact factor: 4.388
Authors: Hans-Gert Bernstein; Johann Steiner; Paul C Guest; Henrik Dobrowolny; Bernhard Bogerts Journal: Schizophr Res Date: 2014-06-16 Impact factor: 4.939
Authors: Т А Prokhorova; I S Boksha; O K Savushkina; E B Tereshkina; Е А Vorobyeva; A N Pomytkin; V G Kaleda; G Sh Burbaeva Journal: Zh Nevrol Psikhiatr Im S S Korsakova Date: 2016
Authors: Irina S Boksha; Maria A Omel'chenko; Olga K Savushkina; Tatyana A Prokhorova; Elena B Tereshkina; Elena A Vorobyeva; Gulnur Sh Burbaeva Journal: Eur Arch Psychiatry Clin Neurosci Date: 2022-03-15 Impact factor: 5.270